Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
The company said certain batches of semaglutide were found to be out of specification due to an issue associated with the API used in the product. It is currently investigating the root cause and taking appropriate corrective measures to ensure product quality.
Dr Reddy's clarified that the issue has no impact on patient safety or the product's existing global regulatory filings. The company added that it remains committed to ensuring reliable global supplies of the metabolic therapy.
The company's management will host a conference call on 9 July 2026 at 4:30 p.m. IST to discuss the development and answer questions from participants.
Hyderabad-based Dr Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
The company reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25.
Powered by Capital Market - Live News